Victory Capital's RS Large Cap Value Strategy highlighted CVS Health Corporation as a beneficiary of improving execution and a favorable payer margin outlook in its second-quarter 2026 investor letter. The strategy initiated its position in early 2025 after shares fell due to prior management's aggressive Medicare Advantage expansion, which drove the Health Care Benefits segment's medical benefit ratio from 84.0% in 2022 to 92.5% in 2024 and compressed operating margins from 6.9% to 0.2%. During the second quarter, CVS reported strong first-quarter results, raised full-year guidance, and saw S&P revise its credit outlook from negative to stable, while the Centers for Medicare & Medicaid Services finalized a 2.5% rate increase for 2027, well above the initially proposed 0.1%, and utilization data pointed to moderating medical cost trends. The combination of higher reimbursement and easing cost pressures is expected to support a meaningful recovery in payer margins, with a credible path to earnings growth over the next two to three years, though the strategy trimmed its position opportunistically to fund other ideas. CVS Health shares closed at $110.60 on July 21, 2026, with a one-month return of 8.57% and a 52-week gain of 78.82%, giving the company a market capitalization of $141.12 billion.
CVS Health CorpCVS raised full-year guidance, S&P revised credit outlook to stable, and the strategy sees a credible path to earnings growth.